Although the rule does not adopt the many drug access protections requested by drug industry stakeholders, it does promise forthcoming guidance regarding HHS expectations for the formulary exceptions process that should be followed by exchange plans.
Drug coverage provisions in the HHS final rule on essential health benefits are basically unchanged from the earlier proposed version.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.
Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.
Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.
Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.
